Fresenius Invests in BioIntellisense AI Platform
“We made this strategic investment in BioIntelliSense to enable our medical staff to more efficiently and effectively continuously monitor patients, facilitating precise and timely interventions and reducing cost to the system,” explains FMCNA CEO, Bill Valle.
Read the full article » | Posted 09-12-2019
Related Articles
- Education Critical to Boosting Home Dialysis, Panel Says I Posted 01-16-2026
- The Annual Dialysis Conference Will be in Kansas City, MO February 26 to March 1 Posted 01-16-2026
- The Forum of ESRD Networks has New Videos for its 2023 Home Dialysis Toolkit Posted 01-16-2026
- Vantive: Real People, Real Stories on PD Empowers Site for Patients Posted 12-17-2025